Your shopping cart is currently empty

Erucin (1-isothiocyanato-4-methylsulfanylbutane) is a dietary isothiocyanate produced by enzymatic hydrolysis of glucoErucin with potential cancer preventive effects, involved in apoptosis and cell cycle blockade through PARP-1 cleavage, p53 and p21,Cyp450, quinone reductase (QR), glutatione transferase (GST) and other pathways.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $40 | - | In Stock | |
| 25 mg | $89 | - | In Stock | |
| 50 mg | $147 | - | In Stock | |
| 100 mg | $218 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | - | In Stock |
| Description | Erucin (1-isothiocyanato-4-methylsulfanylbutane) is a dietary isothiocyanate produced by enzymatic hydrolysis of glucoErucin with potential cancer preventive effects, involved in apoptosis and cell cycle blockade through PARP-1 cleavage, p53 and p21,Cyp450, quinone reductase (QR), glutatione transferase (GST) and other pathways. |
| In vitro | In LPS-stimulated RAW 264.7 macrophages, Erucin (2.5 and 5 μmol/L) inhibited NO and PGE₂ production, suppressed NF-κB activity, and reduced expression of TNF-α, IL-6, IL-1β, iNOS, and COX-2[1]. In SH-SY5Y neuroblastoma cells, Erucin (5 μM) activated the Nrf2 pathway, increased intracellular GSH levels, and protected against 6-OHDA-induced oxidative stress[2]. Erucin (30–100 μM) inhibits proliferation and migration, induces apoptosis, releases H₂S, and reduces ERK1/2 phosphorylation in AsPC-1 pancreatic cancer cells[3]. |
| In vivo | In a TPA-induced mouse ear edema model, Erucin (100 and 300 nmol) significantly reduced swelling and decreased iNOS and COX-2 expression[1]. |
| Synonyms | 4-(Methylthio)butyl isothiocyanate, 1-isothiocyanato-4-methylsulfanylbutane |
| Molecular Weight | 161.29 |
| Formula | C6H11NS2 |
| Cas No. | 4430-36-8 |
| Smiles | S=C=NCCCCSC |
| Relative Density. | 1.03g/cm3 |
| Storage | store under nitrogen,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (496 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (20.46 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.